Are you wondering about using Sarclisa (isatuximab-irfc) as part of myeloma maintenance therapy? Here's what's helpful to know.
Sarclisa is a monoclonal antibody that targets a protein called CD38, which is found in high amounts on myeloma cells. It helps the immune system recognize and destroy those cells. It's not used Show Full Answer
Are you wondering about using Sarclisa (isatuximab-irfc) as part of myeloma maintenance therapy? Here's what's helpful to know.
Sarclisa is a monoclonal antibody that targets a protein called CD38, which is found in high amounts on myeloma cells. It helps the immune system recognize and destroy those cells. It's not used on its own — it's always combined with other myeloma treatments. A newer under-the-skin version called Sarclisa Escena has recently been FDA-approved. It can be given in two ways:
- A healthcare professional gives it manually via a syringe
- Through a hands-free on-body injector device called CirCLIQ
This is a big deal because the traditional IV infusion can take over three hours for the first dose, while the under-the-skin method takes around 6–20 minutes. Clinical trial results showed similar response rates between the two delivery methods — around 71% — so effectiveness isn't compromised by choosing the faster option.
It may also reduce some IV-related reactions like chills, nausea, or blood pressure changes. However, injection-site reactions like redness, pain, or swelling can occur with the under-the-skin version. Other possible side effects to be aware of include:
- Upper respiratory infections
- Fatigue
- Pneumonia
- Muscle, bone, or joint pain
- Diarrhea
- Peripheral neuropathy (numbness or tingling)
- Changes in blood counts (platelets, hemoglobin, white blood cells)
As always, the best approach is to discuss with your care team whether Sarclisa fits your specific treatment history and goals.
August 13
Join
Your Privacy Choices
